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Q1 Júlia García-Pindado,a Soledad Royo,a Meritxell Teixidóa*
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Several natural peptides have a biaryl or biaryl ether motif in their biologically active structures. A model bicyclic pentapeptide
containing a biaryl bridge has been synthesized by solid-phase peptide synthesis combining on-resin Suzuki and Miyaura
cross-coupling reactions. Its biological properties in terms of permeability, stability and cytotoxicity have been studied, demon-
strating the positive contribution of the biaryl bridge, excellent membrane penetration and serum stability Copyright © 2017 Eu-
ropean Peptide Society and John Wiley & Sons, Ltd.
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IntroductionQ4
Natural products are the source of a wealth of bioactive molecules
with particular structural features. Among them, complex cyclic
peptides with a biaryl bridge motif show biologically relevant activ-
ities, such as antimicrobial, proteasome inhibition or cytotoxic [1].
Over recent years, the use of catalyzed cross-coupling reactions
has been extended to solid-phase peptide synthesis (SPPS) [2–6].
In particular, the Suzuki–Miyaura reaction allows C–C bond con-
struction in mild conditions and in a safe environment, thereby
allowing access to drug-like molecules that can mimic the natural
biaryl bond used as a conformational constraint and a site for rec-
ognition of protein surfaces.
One of the most important challenges in medicinal chemistry is
identifying molecules with the ability to permeate across biological
barriers or to increase the transport of cargoes through them. Vari-
ous examples of molecules with this capacity have been reported,
including cyclic and N-methylated polypeptides, among others
[7–10]. The use of a staple motif is focusedmostly on fixing a partic-
ular conformation of a peptide, for instance, the α-helix, thereby im-
proving the pharmacologic parameters that also trigger biological
activities [11,12]. It has also been shown that the introduction of a
staple moiety can increase cell permeability [13].
Following this prior knowledge, a biaryl bicyclic peptide has been
designed, combining both features mentioned earlier (cyclization
and a staple, such as a biaryl bridge), in order to explore how such
a structure behaves in terms of transport across biological
membranes.
Materials and Methods
Protected amino acids were supplied by Iris Biotech (Marktredwitz,
Germany). Wang® resin was obtained from PCAS BioMatrix Inc.
(Quebec, Canada). DIEA, DIPCDI and ninhydrin were purchased
from Fluka Chemika (Buchs, Switzerland) and HOAt from GL
Biochem Shangai Ltd. (Shangai, China). Solvents for SPPS, such as
DMF and DCM, were purchased from SDS (Barcelona, Spain) and
trifluoroacetic acid (TFA) from Scharlau (Barcelona, Spain). Other
chemical reagents were acquired from Aldrich (Milwaukee, WI) with
the highest purity commercially available. Syringes of 20 ml for
SPPS and Eppendorf tubes were provided by Scharlau and Falcon
tubes by Deltalab. PAMPA plates and system solution were sup-
plied by pION (Woburn, MA USA), and porcine polar brain lipid ex-
tract (PBLEP) by Avantis Polar Lipids (Alabaster, AL). The basic
instruments usedwere a lyophilizer (Virtis, Frezzmobile 25 EL), oven
(Selecta, Digitronic), vortex [Merck Eurolab, MELB1719 (EU)], mag-
netic stirrer (IKA, RCT basic), centrifuge (Eppendorf, 5415R), GUT-
BOX™ (pION Aqueous Boundary Layer Thickness @ Double-Sink™),
pipettes (Gilson, Pipetman P2, P20, P200, P1000) and Shimadzu
UV-2501 PC UV–VIS spectrophotometer. HPLC analyses were per-
formed on a Waters Alliance 2695 with an automated injector and
a photodiode array detector 2998 Waters (Waters, Milford, MA)
using a SunFire™ C18 column, 3.5 μm, 4.6 × 100 mm, and
EmpowerPro 2 software. Detection was performed at 220 nm,
and the analyses were carried out with a linear gradient 0–100%
CH3CN (0.036% TFA) in H2O (0.045% TFA) over 8 min at a flow rate
of 1 ml/min. Ultra performance liquid chromatography Q5(UPLC) anal-
yses were performed on aWaters Acquity with an automated injec-
tor and a photodiode array detector Waters (Waters, Milford, MA)
using a BEH C18 column, 1.7 μm, 2.1 × 50 mm, and EmpowerPro 3
software. Detection was performed at 220 nm, and the analyses
were carried out with a linear gradient 0–100 CH3CN, UPLC grade,
(0.036% TFA) in H2O (0.045% TFA) over 2 min at a flow rate of
0.61 ml/min. UPLC-MS analyses were performed on a Waters
Acquity with an automated injector and a photodiode array detec-
tor Waters (Waters, Milford, MA) coupled to an electrospray ion
source ESI-MS Micromass ZQ, using a BEH C18 column, 1.7 μm,
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2.1 × 50 mm, and MassLynx 4.1 software. The instrument was oper-
ated in the positive ESI (+) ion mode. Detection was performed at
220 nm, and the analyses were carried out with a linear gradient
0–100 CH3CN, UPLC grade, (0.07% formic acid) in H2O (0.1% formic
acid) over 2 min at a flow rate of 0.61 ml/min. Samples were intro-
duced, in a volume (1–10 μl) whose absorbance was between 0.2–
0.4, into the mass spectrometer ion source directly through a UPLC
autosampler.
High performance liquid chromatography purification was per-
formed in a Waters system with 2545 binary gradient module, a
2767manager collector, and a 2998 photodiode array detector with
MassLynx 4.1 software. The column usedwas a Sunfire™ C18, 3.5μm,
10 × 150 mm, 100 Å from Waters. The solvents were prepared as
CH3CN (0.1% TFA) and H2O (0.1% TFA). The flow rate was
10 ml/min. HPLC analyses were performed to validate the correct
purification of the peptide. Purity and identity was assessed by an-
alytical UPLC-MS.Mass spectrometry characterization of all the pep-
tides was carried out using a MALDI-TOF Applied Biosystem 4700.
1 μl of the peptide in a solution with a concentration between
0.5–2 mg/ml was mixed with 1 μl of α-ciano-4-hydroxycinnamic
acid (ACH) matrix and then seeded on the MALDI plate and air-
dried. For the matrix, 10 mg/ml solution of ACH was prepared in
CH3CN/H2O 1 : 1 (v/v) with 0.1% TFA.
General Method for Solid-Phase Peptide Synthesis
Solid-phase peptide syntheses were performed at different scales
between 100 and 500 μmols. L-amino acids were used except for
D-proline. Peptide elongations were carried out in 20-ml polypro-
pylene syringes, each fitted with a polypropylene porous disk. Sol-
vents and soluble reagents were removed by filtration. Washings
between steps were performed with DMF (3 × 30 s), MeOH
(3 × 30 s) and DCM (3 × 30 s) using 10 ml of solvent/g resin each
time. During couplings, the resin was stirred using an orbital shaker.
Solid-Phase Miyaura Borylation Adapted from Afonso et al. [2]
The resin was transferred to a glass vial and treated with
bis(pinacolato)diboron (B2Pin2) (4 equiv.), PdCl2) (0.18 equiv.), 1,10-
bis(diphenylphosphanyl)ferrocene (dppf) (0.09 equiv.) and KOAc
(6 equiv.) in DMSO. The mixture was then heated at 85 °C between
24 and 36 h.
The resin was then filtered and washed with DMF, DMF/H2O,
MeOH and DCM. An aliquot of the resulting borono resin was
cleaved with 95% TFA/2.5% H2O/2.5% TISQ6 for 1 h. Following TFA
evaporation, the crude peptide was dissolved in H2O:CH3CN 1 : 1
and then analyzed by HPLC and characterized by MS.
Solid-Phase Suzuki Reaction Adapted fromAfonso et al. [2] and
Doan et al. [5]
The resin was transferred to a glass vial and treated with Cs2CO3 (3
equiv.) and Pd(PPh3)4 (0.1 equiv.) in DMF. The mixture was stirred
and heated at 65 °C for 48 h. The resin was then filtered andwashed
with DMF, MeOH and DCM. After the Suzuki reaction, the peptides
were cleaved from the resin.
Purification of the Crude Peptides
In order to remove remains of palladium (from the Suzuki–Miyaura
and borylation reactions), a Porapak™ RP cartridge was required as
an intermediate purification step prior to the head-to-tail cycliza-
tion of the compounds already bearing the biaryl bridge.
First, the column was washed with MeOH (two volumes) and
equilibrated with H2O (one volume). After the column had dried,
the sample was charged in less than 1.5 ml methanol or CH3CN/
H2O 1 : 1. The gradient started with 100% water, followed by a step
by step increasing of 5%. Manual pressure was applied to achieve a
constant flux and facilitate elution.
Samples of the fractions were injected in the HPLC and HPLC-MS
apparatuses in order to detect the product. Those fractions contain-
ing the peptide were collected and lyophilized. The flow rate and
the size of the Porapak column were selected taking into account
the amount of crude peptide to be purified.
Final HPLC-semipreparative purification was carried out.
Head-to-Tail Cyclization in Solution
After cleavage from the resin and Porapak™ purification, linear or
linear stapled peptides were treated with PyBOP (2 equiv.), HOAt
(1 equiv.), DIEA (6 equiv.) in DCM/ 1% DMF (final concentration
1 mM) at room temperature for 24–48 h.
A final purification step by RP-HPLC on a C18 column was re-
quired to obtain the pure cyclic peptides.
Amino Acid Derivatization pNZ-(4I)-Phe-OH [14]
The amino acidwas prepared from 2 g (6.88mmol) of H-(4I)Phe-OH.
p-Nitrobenzyl chloroformate (1 equiv.) was dissolved in dioxane
(3 ml). Sodium azide (1.2 equiv.), previously dissolved in water
(2 ml), was added to this solution. This mixture was vigorously
stirred at room temperature for 3 h. The amino acid dissolved in di-
oxane (16 ml) and 2% aq. NaHCO3 (16 ml) was then introduced
dropwise. The mixture was allowed to react for 24 h at room tem-
perature. The pH was kept at 9–10 and readjusted when needed.
Completion of the reaction was monitored by thin layer chroma-
tography (TLC).
The crude product was separated in 50% H2O/50% MTBE Q7
(100 ml), and the aqueous phase was extracted with MTBE
(2 × 50 ml). The pH was adjusted to 4 with aqueous HCl 12 N. The
product precipitated as a white solid. Finally, it was filtered, washed,
resuspended in water and lyophilized.
Loading of the First Amino Acid onto Wang Resin
The peptides were synthesizedmanually on solid-phase using stan-
dard Fmoc/tBu chemistry. Wang resin (1.42 mmol/g) was used as
support. Coupling of the first amino acid Fmoc-D-Pro-OH (8 equiv.)
was performed using DIPCDI Q8(4 equiv.) in 90% DCM/10% DMF and
DMAP (0.8 equiv.) at room temperature overnight. The solution was
filtered, and the resin was washed with DMF, DCM and MeOH sev-
eral times. The Fmoc group was removed by treatment with 20%
piperidine solution in DMF (1 × 5, 1 × 10 and 1 × 15 min), and the
loading of the resin was quantified by measuring the absorbance
of the filtrate at 290 nm (ε = 5900). The capping of the remaining
reactive positions of the resin was carried out with acetic anhydride
(20 equiv.) and DIEA (20 equiv.) in DMF at room temperature for
30 min. The resin was washed again with DMF, DCM and MeOH.
Loading of the First Amino Acid onto Chlorotrityl Resin
The peptides were synthesized manually on solid-phase using
Fmoc standard chemistry. 2-CTC resin was used as support
(1.57 mmol/g), and the coupling of the first amino acid Fmoc-D-
Pro-OH (1 equiv.) was performed with DIEA (3 equiv.) in 15% DMF
and 85% DCM at room temperature for 20 min. An extra excess
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of DIEA (3 equiv.) was then added, and the mixture was stirred and
allowed to react for 90 min. At this point, 0.8 ml/g resin MeOH was
added, and the reaction was maintained for another 15 min. When
the time was over, the solution was filtered, and the resin was
washedwith DMF and DCM several times. Loadingwas determined
as for the Wang resin.
Identification Tests
After each reaction, the Kaiser test [15] was used to identify primary
amines on the N-terminus of the elongating peptide on the solid
support. The chloranil test [16] was used to identify secondary
amines.
Cleavage Conditions
Peptides were cleaved from theWang resin using a mixture of 95%
TFA, 2.5% H2O and 2.5% TIS. The peptides were stirred for 90 min
with the cocktail. The compounds were then filtrated and washed
with DCM. After reducing the volume under a nitrogen flux, they
were resolved with CH3CN:H2O 1 : 1 and lyophilized.
Regarding the sequences prepared with 2-chlorotrityl resin,
cleavage was performed with 50% TFA, 45% DCM and 5% H2O.
Synthesis and Characterization of the Peptides
In the manuscript, we follow for brevity the nomenclature described in
[17] cyclo(Lys-(4&)Phe-Lys-(4&)Phe-D-Pro)
The peptide was prepared starting from Fmoc-D-Pro-Wang resin.
The Fmoc group was removed with 20% piperidine in DMF
(1 × 5 min, 1 × 15 min). The second amino acid was introduced as
pNZ-(4I)Phe-OH (3 equiv.) and coupled to DIPCDI (3 equiv.) and
HOAt (3 equiv.) in DMF at room temperature for 90 min. Comple-
tion of the coupling was checked by the chloranil test. pNZ was
then removed with a solution of 6 M SnCl2 and 1.6 mM
HCl/dioxane (3 × 30 min). The resin was washed with DMF,
DMF/H2O, H2O/THF, THF, MeOH and DCM (3× each). Trt-Lys(-
Fmoc)-OH was coupled to PyBOP (3 equiv.) and DIEA (6 equiv.) in
DMF at room temperature for 1 h. After Fmoc removal, pNZ was in-
troduced using pNZCl (3 equiv.) and DIEA (30 equiv.) in DMF at
room temperature (2 × 45 min). At tripeptide level, Miyaura
borylation was performed following the general method for this re-
action on-resin. The Trt group was then removed with 2% TFA/2%
H2O/96% DCM (3 × 5 min, 1 × 20 min). Between the treatments,
the resin was washed twice with DCM and, after the last one, also
with a solution of 5% DIEA/95% DCM. Fmoc-(4I)-Phe-OH (3 equiv.)
was introduced with DIPCDI (3 equiv.) and oxyme (3 equiv.) in
DCM/DMF. Again, deprotection of the Fmoc group preceded the
coupling of the last amino acid Boc-Lys(pNZ)-OH (3 equiv.), which
was activated with TBTU (3 equiv.) and DIEA (6 equiv.). The Suzuki
reaction was performed following the general method. Cleavage
from the resin was then carried out with a mixture of 50%
TFA/45% DCM/5% H2O under stirring for 1 h at room temperature.
After TFA evaporation, the crude product was dissolved in 50%
H2O/50% CH3CN and lyophilized. Palladium was then removed by
elution through a Porapak™ RP cartridge with increasing amounts
of CH3CN in H2O. The fractions containing the product, even when
not completely pure, were pooled and lyophilized. To finish the syn-
thesis, the peptide was cyclized using the general method, and
next, pNZ in lysines side chains was removed by means of Na2S2O4
(8 equiv.) and amixture of equal parts of H2O, CH3CN and EtOH [18].
After 24 h, the reagents were added again, and at 48 h, the reaction
was completed. The solvent was then evaporated, and the crude
peptide was dissolved in CH3CN:H2O 1 : 1, lyophilized, analyzed
by HPLC and characterized by MS. This crude product was purified
by HPLC, and the fractions were lyophilized again.
High-performance liquid chromatography tR (G 0–100% CH3CN/
H2O in 8 min): 8.0 min; UPLC tR (G 0–100% CH3CN/H2O in 2 min):
1.8 min; UPLC-MS tR (G 0–100% CH3CN/H2O in 2 min): 1.8 min,
[M + H+]expected = 645.36, [M + H
+]found = 645.44, HRMS (ESI): calcd.
For C35H48N7O5 645.3533; [M + H
+]found = 645.3536; yield (synthe-
sis + purification): 1%.
H-Lys-Phe-Lys-Phe-D-Pro-OH
This peptide was prepared from Fmoc-D-Pro-CTC resin (1
equiv. = 0.58 mmol). Fmoc-Phe-OH and Fmoc-Lys(Boc)-OH residues
(3 equiv.) were attached using DIPCDI (3 equiv.) and HOAt (3 equiv.)
as coupling agents. Cleavage of the peptidyl sequence provided
the desired peptide.
High-performance liquid chromatography tR (G 0–100% CH3CN/
H2O in 8 min): 4.1 min; UPLC tR (G 0–100% CH3CN/H2O in 2 min):
1.3 min; UPLC-MS tR (G 0–100% CH3CN/H2O in 2 min): 1.3 min,
[M + H+]expected = 666.39, [M + H
+]found = 666.29, HRMS (ESI): calcd.
For C35H52N7O6 666.3974; [M + H
+]found = 666.3970; yield (synthe-
sis + purification): 44%.
Cyclo(Lys-Phe-Lys-Phe-D-Pro)
This peptide was prepared by cyclization of previously synthesized
linear peptide (H-Lys-Phe-Lys-Phe-D-Pro-OH) following the general
cyclization method. Cleavage conditions in this synthesis involved
2% TFA/98% DCM to maintain Boc protecting groups in lysine side
chains. Boc removal in solution was achieved by adding a 75%
TFA/25% DCM solution to the peptide. The mixture was stirred at
room temperature for 4 h. The reaction was monitored by TLC
(50% AcOEt/ 50% DCM) using the ninhydrin staining solution. The
solvent was evaporated, and the crude product was dissolved in
CH3CN:H2O 1 : 1, lyophilized, analyzed by HPLC and characterized
by MS.
High-performance liquid chromatography tR (G 0–100% CH3CN/
H2O in 8 min): 6.0 min; UPLC tR (G 0–100% CH3CN/H2O in 2 min):
1.4 min; UPLC-MS tR (G 0–100% CH3CN/H2O in 2 min): 1.4 min,
[M + H+]expected = 648.38, [M + H
+]found = 649.23, HRMS (ESI): calcd.
For C35H50N7O5 648.3868; [M + H
+]found = 648.3878; yield (synthe-
sis + purification): 15%.
H-Lys-(4&)Phe-Lys-(4&)Phe-D-Pro-OH
The peptide was synthesized from Fmoc-D-Pro-CTC resin
(1 eq = 0.53 mmol). The same procedure as for the bicyclic peptide
was used to prepare this sequence. The Trt-Lys(Fmoc)-OH residue
was required as in the bicyclic peptide synthesis. In this particular
sequence, Fmoc was exchanged for Boc to facilitate removal of
these protecting groups concomitantly in the final cleavage. Cleav-
age of the sequence provided the desired unprotected peptide.
High-performance liquid chromatography tR (G 0–100% CH3CN/
H2O in 8 min): 5.3 min; UPLC tR (G 0–100% CH3CN/H2O in 2 min):
1.3 min; UPLC-MS tR (G 0–100% CH3CN/H2O in 2 min): 1.3 min,
[M + H+]expected = 664.37, [M + H
+]found = 664.49, HRMS (ESI): calcd.
For C35H50N7O6 664.3817; [M + H
+]found = 664.3818; yield (synthe-
sis + purification): 3%.
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Parallel Artificial Membrane Permeability Assay
The parallel artificial membrane permeability assay (PAMPA) was
used to measure the capacity of the peptides to cross the blood–
brain barrier (BBB) by passive diffusion. The effective permeability
(Pe) of the compounds was determined at an initial concentration
of 200 μM. The buffer solution was prepared from a commercially
concentrated one, supplied by pION. Following the manufacturer’s
instructions, system solution was adjusted to pH 7.4 using a 0.5 M
NaOH solution. The peptides were dissolved in a mixture of buffer
solution with 20% of 1-propanol used as cosolvent. The PAMPA
sandwich was separated, and the donor well was filled with
195 μl of the compound solution of interest. A magnetic stirrer
was placed in each well. The acceptor plate was put into the donor
plate, ensuring that the underside of the membrane was in contact
with the buffer. Then, 4 μl of a mixture of phospholipids from a por-
cine polar brain extract (20 mg/ml) in dodecane (composition:
12.6% phosphatidylcholine (PC), 33.1% phosphatidylethanolamine
(PE), 18.5% phosphatidylserine (PS), 4.1% phosphatidylinositol (PI),
0.8% phosphatidic acid and 30.9% of other compounds) was added
to the filter of each well, followed by 200 μl of buffer solution. The
plate was then covered and incubated at room temperature in a
saturated humidity atmosphere for 4 h under orbital agitation at
25 μm of unstirred water layer. After this period, 165 μl/well of
the solution from the donor and acceptor plates was transferred
to the HPLC vials, except for the bicyclic compound, for which all
the fractions were pooled. One-hundred microliter of each linear,
stapled and cyclic acceptor samples and 80 μl of the bicyclic accep-
tor were injected into the HPLC apparatus. Transport was also con-
firmed by HPLC-MS, which indicated that the integrity of the
peptides was preserved. Regarding the donor and initial time sam-
ples, the linear compound was injected at 1 μl, the linear stapled
peptide at 20 μl, the head-to-tail cyclic peptide at 10 μl and the bi-
cyclic peptide at 5 μl.The bicyclic acceptor was injected again at 1
and 5 μl owing to the initial large absorbance obtained.
The effective permeability after 4 h was calculated using Eqn (1)
and the percentage of transport using Eqn (2).
T %ð Þ ¼ CA tð Þ
CD t0ð Þ 100 (1)
Pe ¼ 218:3t  log 1
2CA tð Þ
CD t0ð Þ
 
106cm=s (2)
where t is time (h), CA(t) is the peptide concentration in the acceptor
well at time t and CD(t0) is the peptide concentration in the donor
well at 0 h. Membrane retention (%R) was calculated from the dif-
ference between the total starting amount of peptide and the
amount of peptide in the donor and acceptor wells at the end of
the assay after 4 h.
Peptide Stability in Human Serum
Peptides at a final concentration of 3 mM were dissolved in HBSSQ9
and incubated at 37 °C in the presence of 90% human serum for
24 h. At different incubation times (30 min, 1, 3, 6, 10, 12 and
24 h), 50 μl aliquots were treated with 200 μl of methanol to precip-
itate serum proteins. After 30 min of centrifugation at 4 °C, the su-
pernatant was filtered and then analyzed by RP-HPLC to calculate
the percentage of intact peptide in the sample.
Cytotoxicity, MTT assay.
Twenty-four hours before starting the assay, 3500 HeLa cells were
seeded in 96-well plates. After this period, cells with peptides at 200
and500μM inDMEM Q10(1mg/ml glucose) supplementedwith 10%se-
rumwere incubated for 24 h. After 22h,MTT reagentwas added to a
final concentration of 0.5mg/ml. After a 4 h incubation, themedium
wasdiscarded, and thepurple crystals of formazanwere dissolved in
200 μl of DMSO. The plate was shaken for 30 min, and absorbance
was measured at 570 nm. Cell viability was calculated by dividing
the absorbance of wells treated with a given peptide by the absor-
bance of the untreatedwells.Measurementswere performed in trip-
licate. As a positive control, cells were incubatedwith 1% SDS.
Results and Discussion
Design of Bike Peptides
As a model, a pentapeptide sequence was chosen (Figure F11), as five
amino acid rings are formed at reasonable yields and without fur-
ther difficulties, rendering molecules with sufficient rigidity con-
ferred by the presence of the biaryl staple motif.
Because we focused on exploring the capacity of the bike pep-
tide to cross biological barriers, the most suitable amino acids were
selected for the remaining two positions on the basis of achieving
equilibrium between hydrophocity and hydrophilicity in order to
avoid membrane retention. Furthermore, satisfactory solubility of
the molecules should be ensured, as well as the presence of posi-
tive charges, whose introduction is widely used for protein–protein
interactions (PPIs) once inside the brain [19–21].
For all these reasons, the selected two remaining residues were
lysines, a good building block as it favors PPIs.
Synthesis and Characterization of Bike Peptides and Other
Control Sequences
Figure F22 shows the synthetic scheme followed for the synthesis of
the sequence cyclo(Lys-(4&)Phe-Lys-(4&)Phe-D-Pro). Some
Figure 1. Structure of the general scaffold for the bicyclic peptides.
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modifications to the standard Fmoc/tBu protocols [22] were re-
quired, and the synthetic route included an on-resin borylation,
an intramolecular solid-phase Suzuki–Miyaura reaction and an in
solution head-to-tail cyclization.
Briefly, the peptide was synthesized on solid-phase using
Fmoc/tBu chemistry. Wang resin was chosen as the best option be-
cause it provides the linear peptide with a C-terminal carboxylic
acid and is stable under the required reaction conditions [23],
whereas 2-chlorotrytil resin would be labile during deprotection
of the main chain protecting group after Miyaura borylation. D-Pro-
line was selected as C-terminal amino acid on the resin in order to
later favor cyclization in solution and provide extra rigidity to the
overall structure of the peptide. It must be taken into account that
this sequence is highly prone to diketopiperazine (DKP) formation
because of the presence of proline in the C-terminus and specifi-
cally because the sequences of the first and second amino acid
are L-D in terms of configuration [24]. Furthermore, Wang resin does
not prevent DKP formation. Therefore, the second amino acid was
introduced as a pNZ derivative to avoid DKP formation [14] during
the N-terminal deprotection in basic conditions. Mild coupling con-
ditionswere chosen in order to avoid side reactions. Therefore, cou-
plings were performed with DIPCDI, even in the case of coupling
onto secondary amines such as Pro. When the amino acid to be
coupled was protected with Trt, phosphonium salts were used
due to stronger conditions required for the coupling of this hin-
dered amino acid derivative [23,25]. Another important point to
take into account is the pH of the medium before the coupling of
third amino acid. After removal of pNZ, the medium must be neu-
tralized because deprotection takes place in acidic conditions. Nev-
ertheless, deprotection can be performed by in situ neutralization
during the next coupling with a base like DIEA, commonly used in
combination with coupling agents such as PyBOP [23,24]. Regard-
ing the third residue, it was introduced with a Trt protecting group
in the backbone and Fmoc in the side chain, which was subse-
quently substituted by pNZ. The biaryl staple was formed between
two phenylalanines introduced in the sequence. For this, p-iodine
phenylalanines were selected, performing Miyaura borylation on
one of them. We decided to perform Miyaura borylation at the
tripeptide level as a dipeptide is too small to be followed by
HPLC-MS. In addition, borylation on the second residue could imply
steric hindrance from the resin.
One of the most important aspects of designing the synthesis of
these peptides was the selection of orthogonal protecting groups.
Figure F33 shows all the protecting groups tested and their viability.
It is worth noting that there are different factors like medium con-
ditions, reagents or resin that influence this selection. For the
borylation and Suzuki reaction steps, the presence of base and cat-
alyst reduces the number of compatible protecting groups. These
groups cannot be base-labile, because the free amine is not com-
patible with these reactions, and it is important to avoid simulta-
neous deprotection. In addition, the protecting group should be
compatible with an acid-labile resin, such as Wang resin. Fmoc is
not stable under basic conditions, while Boc is stable under
borylation but is not compatible with elongation on acid-labile
resins. Also, Alloc is not stable in the presence of Pd, which is used
in the Suzuki–Miyaura reactions. Finally, Trt and pNZ are both stable
under borylation and compatible with some acid-labile resins such
as Wang resin.
The side chain of lysines should also be protected with orthogo-
nal protecting groups, which may be removed in solution at the
end of the synthesis after head-to-tail cyclization in solution. pNZ
was the most suitable group as it showed orthogonality with the
synthetic strategy, including stability to the cleavage conditions
(95% TFA containing cleavage cocktails) and the possibility to be re-
moved in solution once the bicyclic peptide had been obtained.
The Suzuki reaction was performed on-resin to build the biaryl
bridge between the two aromatic residues, and when it was com-
plete, cleavage from the resin was carried out. Head-to-tail cycliza-
tion was performed under high dilution to hinder the
intermolecular reaction and favor the intramolecular one, because
our aim was to obtain a bicyclic peptide and prevent undesired di-
merization. The last step was the in solution removal of pNZ
protecting groups on lysines, which was carried out in reductive
conditions with Na2S2O4 [17].
Palladium is used in small amounts as a catalyst in both
borylation and the Suzuki reaction. Although the crude product ob-
tained after cyclization will always require a final purification, the re-
moval of palladium before performing cyclization in solution is
mandatory because this compound can interfere with the reactivity
of the amine.
Palladium can be removed in several ways, including through the
use of chelating species [26], which attach to this metal to form a
Figure 2. Solid-phase peptide synthesis cyclo(Lys-(4&)Phe-Lys-(4&)Phe-D-Pro).
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soluble complex, thereby leaving the solution free of palladium. It is
also possible to treat the cleaved peptide with a scavenger resin
specific for this element. However, such methods are useful only
when the amount of palladium is really low, not the current case.
Another option is to use a Porapak™ reversed-phase cartridge.
While this method does not provide a completely pure linear pep-
tide, it is efficient in removing palladium and other impurities in a
simple and rapid manner.
Therefore, after the Suzuki reaction and cleavage of the peptide
from the resin, palladium is removed by using a Porapak™ reversed-
phase cartridge. The small traces of palladium that might remain in
the crude product does not interfere with the cyclization and is fi-
nally removed in the last purification step, which is performed by
semipreparative HPLC.
In addition to the bicyclic bike peptide, a cyclic analog with the
two unmodified Phe [cyclo(Lys-Phe-Lys-Phe-D-Pro)] was synthe-
sized. By comparison to the bicyclic peptide, the relevance of the
biaryl staple motif can be studied. Furthermore, we synthesized
the linear version of the peptide (H-Lys-Phe-Lys-Phe-D-Pro-OH),
which also provides information related to the influence of the
head-to-tail cyclization, and the linear stapled peptide (H-Lys-(4&)
Phe-Lys-(4&)Phe-D-Pro-OH), which enables to test the effect of this
staple motif alone, without including the head-to-tail cyclization
constrain (FigureF4 4).
The linear pentapeptide was synthesized using standard
Fmoc/tBu SPPS with chlorotrityl resin and concomitant cleavage
and deprotection of the Boc side-chain protecting group. The
head-to-tail cyclic peptide was prepared following a similar proto-
col using mild cleavage conditions (2% TFA/98% DCM) to maintain
lysine side chains protected until the cyclization in solution was fin-
ished. Once the cyclic peptide had formed, Boc removal in solution
was carried out. The linear stapled peptide was prepared with the
same protocol as that used for the bicyclic molecule but using
Boc as lysine side-chain protecting group, which was later removed
during cleavage.
Permeability across Biological Barriers
Drug targeting to the brain has gained relevance over the years ow-
ing to the number of diseases that affect the central nervous sys-
tem, such as Alzheimer’s and Parkinson’s diseases, schizophrenia
or epilepsy, among others. In this field, peptides are experiencing
their golden era. Nevertheless, a limitation shared by the vast ma-
jority of potential drug candidates concerns their ability to cross
the BBB [27,28].
Commonly known as a shell, brain parenchyma is protected from
harmful substances in circulating blood by three barriers that also
modulate the entry of some particular molecules. These are the
BBB, which is found in the capillaries; the blood–cerebrospinal fluid
barrier, comprised by the choroid plexus epithelium, and the
ependyma, which is placed at the interphase between the cerebro-
spinal fluid and the brain.
The BBB is a physical and enzymatic barrier formed mainly by
brain capillary endothelial cells. However, other cell types, such as
astrocytes, pericytes and neurons, also play a relevant role in regu-
lating permeability of the BBB. The cells forming the BBB differ from
others because they have very few endocytotic vesicles, thus limit-
ing the amount of transcellular flux, and they form tight junctions,
Figure 3. Protecting group (PG) scheme for the synthesis of the bicyclic peptide cyclo(Lys-(4&)Phe-Lys-(4&)Phe-D-Pro).
J. GARCÍA-PINDADO ET AL.
wileyonlinelibrary.com/journal/jpepsci Copyright © 2017 European Peptide Society and John Wiley & Sons, Ltd. J. Pept. Sci. 2017
6
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
which are responsible for the limited paracellular diffusion and a
minimal level of pinocytosis. Furthermore, efflux transporters and
multidrug-resistant proteins avoid the transcytosis of some com-
pounds. Therefore, one of the remaining existing transport mecha-
nisms at the BBB is passive diffusion [27,29–33].
We therefore question whether the imposed rigidity conferred
by a biaryl bridge could be an advantageous property of our com-
pounds in terms of transport by passive diffusion across biological
membranes such as the BBB.
In order to evaluate the permeability of our peptides, we selected
the PAMPA, which requires small amounts of the compounds and is
simple, fast and inexpensive. It is the gold standard method for
assessing transport by passive diffusion permeation of these com-
pounds and shows good correlation with the in vivo context. Ini-
tially, described by Kansy [34], the PAMPA is based on a 96-well
plate and consists of an artificial membrane that is coated with
phospholipids, mimicking the membrane of study but has no
means for active or paracellular transport. We used an extract of
lipids from porcine brain to mimic the BBB [35]. Propranolol, a β-
adrenergic receptor blocker, was used as control. The ability of
these peptides to cross the BBB is shown inQ11 TableT1 1.
The four compounds showed high permeability across the
PAMPA membrane, all with an effective permeability higher than
1 × 106 cm/s, which correlates to a good transport prediction
in vivo [34]. Nonetheless, it is worth noting that the values obtained
for the peptides displaying the biaryl motif were one order of mag-
nitude higher than those lacking this staple (FigureF5 5), thus imply-
ing that this structural feature favors transport across the BBB by
passive diffusion. Therefore, it may be concluded that a biaryl staple
can be introduced to increase the permeability of linear and cyclic
peptides, while cyclization itself is not as powerful as a tool in terms
of increasing transport across membranes.
Low unwanted retention in the membrane was observed after
calculating the mass balance for these peptides. Of note, high
membrane retention is not always an indication of better transport
as it could reflect that the compound is trapped in the membrane
and is thus unable to reach the brain side of the barrier.
On the basis of these results, we conclude that the biaryl staple is
a powerful tool that can be used to enhance the transport of linear
and/or cyclic peptides by passive diffusion, thus enriching the
existing chemical toolbox for this purpose. The peptidomimetics
obtained in the present study show permeability values of interest
that deserve further consideration.
Protease Resistance of Bike Peptides
Having explored the high potential of stapled peptides with respect
to increasing passive transport, we extended the study to other
properties such as protease resistance.
The high potential of peptides as therapeutic agents is some-
times reduced because of their poor resistance to proteases, which
results in in vivo fragility of these molecules [36]. In this regard, fur-
ther development of protease-resistant peptides is required.
Cyclic peptides typically show better stability inside the human
body as their constrained structures prevents amino and
carboxipeptidase degradation andmakes it more difficult for endo-
peptidases to gain access to them and degrade the compounds.
Nonetheless, there are other privileged structures whose lability is
also reduced, such as N-methylated peptides and peptidomimetics,
including non-natural residues [33–35,37–40].
Figure 4. Ultra performance liquid chromatography chromatogram of the pure peptides in a gradient 0–100% CH3CN in 2 min. Column BEH C18, 1.7 μm,
2.1 × 50 mm. (A) linear, (B) head-to-tail cyclic, (C) linear stapled and (D) bicyclic peptides.
Table 1. Percentage of transport (%T) and effective permeability (Pe) in
the PAMPA after 4 h
Compound Pe(×10
6)
cm/s
T(%) (4 h)
Bicyclic: cyclo(Lys-(4&)Phe-Lys-(4&)Phe-D-Pro) 14.3 ± 3.3 22.6 ± 0.6
Linear stapled: H-Lys-(4&)Phe-Lys-(4&)
Phe-D-Pro-OH
9.2 ± 1.8 16 ± 2.6
Head-to-tail cyclic: cyclo(Lys-Phe-Lys-Phe-D-Pro) 1.4 ± 0.1 2.9 ± 0.2
Linear: H-Lys-Phe-Lys-Phe-D-Pro-OH 1.5 ± 0.1 3.1 ± 0.3
Propranolol 5.8 ± 0.5 18.2 ± 0.8
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Here, we sought to test the effect of the biaryl bridge on the
biostability of these peptides. In this regard, we compared the four
analogs (linear, linear stapled, head-to-tail cyclic and bicyclic
versions).
We first evaluated biostability in human serum. The linear pep-
tide was degraded in less than 30 min, thereby demonstrating
the low biostability of general linear peptides (FigureF6 6). The
head-to-tail cyclic and the linear stapled versions of the peptides
showed enhanced biostability, with half-lives close to 3 h. Finally,
the bicyclic analogwas themost stable compound. Indeed, even af-
ter 24 h of incubation, no significant degradation was observed for
this peptide.
On the basis of these results, we conclude that the introduction
of the biaryl staple into a peptidic scaffold can provide compounds
with increased values of permeability, as well as enhanced protease
resistance – two properties of great interest for the design of novel
drug candidates.
Cytotoxicity of Bike Peptides
After studying the benefits of introducing the biaryl bridge into the
scaffolds, we also explored whether this motif induced extra cyto-
toxicity to these compounds.
The four peptide analogs were tested by the MTT assay in HeLa
cells and at two concentrations (200 and 500 μM). None of the com-
pounds showed significant cytotoxicity (TableT2 2).
However, at the highest concentration tested (500 μM), the linear
stapled peptide and the bicyclic analogs proved more cytotoxic
than the linear and head-to-tail cyclic versions; nevertheless, these
values were not alarming in any case. This cytotoxicity can be ex-
plained by the higher biostability of these analogs. The degradation
of the other two compounds (linear and head-to-tail) implies a
short contact time with the cells and therefore lower toxicity.
Conclusions
This work is a good example of the introduction of organic reac-
tions such as Miyaura borylation and Suzuki cross-coupling on-
resin. Here, we have prepared a distinct kind of bicyclic peptides
(bike peptides) by introducing a biaryl staple bridge in its scaffold.
This approach has proved to be an interesting tool through which
to increase transport across the BBB by passive diffusion, as well
as to enhance serum stability without causing cytotoxicity.
This approach paves the way to introducing the biaryl motifs to
other peptides and then improving their permeability and
protease-resistance.
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During the copyediting of your paper, the following queries arose. Please respond to these by annotating your proofs with the nec-
essary changes/additions.
• If you intend to annotate your proof electronically, please refer to the E-annotation guidelines.
• If you intend to annotate your proof bymeans of hard-copymark-up, please use the standard proofing marks. If manually writing
corrections on your proof and returning it by fax, do not write too close to the edge of the paper. Please remember that illegible
mark-ups may delay publication.
Whether you opt for hard-copy or electronic annotation of your proofs, we recommend that you provide additional clarification of
answers to queries by entering your answers on the query sheet, in addition to the text mark-up.
Query No. Query Remark
Q1 AUTHOR: ORCID ID [0000-0001-8381-1797] does not return a valid ORCID profile
when checked against the ORCID registry. Please provide the correct ORCID ID.
Q2 AUTHOR: Please check that authors and their affiliations are correct.
Q3 AUTHOR: Please supply a graphical table of contents entry with no more than 80 words
or 3 sentences of text summarising the key findings presented in the paper and a figure that
best represents the scope of the paper.
Q4 AUTHOR: Please check if section headings are presented correctly.
Q5 AUTHOR: “Ultra performance liquid chromatography.” Is this the correct definition for
UPLC? Please change if this is incorrect.
Q6 AUTHOR: Please define TIS if this is an abbreviation/acronym.
Q7 AUTHOR: Please define MTBE if this is an abbreviation/acronym.
Q8 AUTHOR: Please define DIPCDI if this is an abbreviation/acronym.
Q9 AUTHOR: Please define HBSS if this is an abbreviation/acronym.
Q10 AUTHOR: Please define DMEM if this is an abbreviation/acronym.
Q11 AUTHOR: “The ability of these peptides to cross the BBB is shown in Table 1.” This
sentence has been reworded for clarity. Please check and confirm if correct.
Q12 AUTHOR: Please provide the page range for this chapter in Reference.
Q13 AUTHOR: Please provide the page range for this chapter in Reference.
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Required software to e-Annotate PDFs: Adobe Acrobat Professional or Adobe Reader (version 7.0 or 
above). (Note that this document uses screenshots from Adobe Reader X) 
The latest version of Acrobat Reader can be downloaded for free at: http://get.adobe.com/uk/reader/ 
 
Once you have Acrobat Reader open on your computer, click on the Comment tab at the right of the toolbar:  
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Replace (Ins) Tool – for replacing text. 
 
Strikes a line through text and opens up a text 
box where replacement text can be entered. 
How to use it 
 Highlight a word or sentence. 
 Click on the Replace (Ins) icon in the Annotations 
section. 
 Type the replacement text into the blue box that 
appears. 
This will open up a panel down the right side of the document. The majority of 
tools you will use for annotating your proof will be in the Annotations section, 
pictured opposite. We’ve picked out some of these tools below: 
2. Strikethrough (Del) Tool – for deleting text. 
 
Strikes a red line through text that is to be 
deleted. 
How to use it 
 Highlight a word or sentence. 
 Click on the Strikethrough (Del) icon in the 
Annotations section. 
 
 
3. Add note to text Tool – for highlighting a section 
to be changed to bold or italic. 
 
Highlights text in yellow and opens up a text 
box where comments can be entered. 
How to use it 
 Highlight the relevant section of text. 
 Click on the Add note to text icon in the 
Annotations section. 
 Type instruction on what should be changed 
regarding the text into the yellow box that 
appears. 
4. Add sticky note Tool – for making notes at 
specific points in the text. 
 
Marks a point in the proof where a comment 
needs to be highlighted. 
How to use it 
 Click on the Add sticky note icon in the 
Annotations section. 
 Click at the point in the proof where the comment 
should be inserted. 
 Type the comment into the yellow box that 
appears. 
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For further information on how to annotate proofs, click on the Help menu to reveal a list of further options: 
5. Attach File Tool – for inserting large amounts of 
text or replacement figures. 
 
Inserts an icon linking to the attached file in the 
appropriate pace in the text. 
How to use it 
 Click on the Attach File icon in the Annotations 
section. 
 Click on the proof to where you’d like the attached 
file to be linked. 
 Select the file to be attached from your computer 
or network. 
 Select the colour and type of icon that will appear 
in the proof. Click OK. 
6. Add stamp Tool – for approving a proof if no 
corrections are required. 
 
Inserts a selected stamp onto an appropriate 
place in the proof. 
How to use it 
 Click on the Add stamp icon in the Annotations 
section. 
 Select the stamp you want to use. (The Approved 
stamp is usually available directly in the menu that 
appears). 
 Click on the proof where you’d like the stamp to 
appear. (Where a proof is to be approved as it is, 
this would normally be on the first page). 
7. Drawing Markups Tools – for drawing shapes, lines and freeform 
annotations on proofs and commenting on these marks. 
Allows shapes, lines and freeform annotations to be drawn on proofs and for 
comment to be made on these marks.. 
How to use it 
 Click on one of the shapes in the Drawing 
Markups section. 
 Click on the proof at the relevant point and 
draw the selected shape with the cursor. 
 To add a comment to the drawn shape, 
move the cursor over the shape until an 
arrowhead appears. 
 Double click on the shape and type any 
text in the red box that appears. 
